Hungarian Investment Promotion Agency

Becton Dickinson (BD), specializing in the production of medical devices, announced the investment in December 2025. The project contributes to the company’s business diversification and strengthens its market presence.

Until now, the U.S.-based company has manufactured prefilled syringes, as well as equipment and laboratory materials for immunology and cell biology research. This development represents a new, high value-added initiative, primarily aimed at sterilizing products manufactured on-site.

The creation of the new sterilization plant introduces an entirely new service and manufacturing function. As a result, the company will be able to cover the full spectrum of the production process—from suppliers, through sterilization, all the way to the end-user.

The project, which will create 25 new jobs with high added value, is of strategic importance, as the establishment of the new plant will make BD the only European prefillable glass syringe manufacturer with its own sterilization capacity. More than a quarter (26%) of the company's suppliers are Hungarian firms, meaning that a significant portion of the production directly supports the domestic economy.

The development reflects a commitment to conscious logistical planning and sustainable operations, as bringing sterilization in-house reduces transport time considerably. The project also eliminates shipments to the Netherlands and Belgium, where products manufactured at the Környe facility were previously sterilized.

As part of the initiative, educational cooperation is being further strengthened. In addition to existing vocational training partnerships, a university dual-education program will be launched, involving 10 students in day-to-day operations.